Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension

Abbott120 enrolled

Overview

This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Hypertension

Interventions

trandolapril/verapamilDRUG

180/2 mg QD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertension Exclusion Criteria: * SBP \> 180 mm Hg, DBP \> 114 mm Hg * Subject has a hypersensitivity to trandolapril or verapamil

Locations (1)

Global Medical Information-Abbott

North Chicago, Illinois, United States

Outcomes

Primary Outcomes

Change in blood pressure from baseline/blood pressure control

Time frame: Baseline to 3 months of Tx

Secondary Outcomes

Absolute BP reduction from baseline, safety

Time frame: Baseline to 3 months of Tx

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.